青青草a国产免费观看|91麻豆精品国产福利|国产av五无码一级毛片|亚洲爆乳精品无码一区二区|久久亚洲AV成人无码国产|91无码人妻一区二区三区|色婷婷av一区二区三区性色|国产制服91一区二区三区制服,女人书籍排行榜,盗墓笔记小说txt下载,玄幻小说排行榜完本

position: EnglishChannel  > Insight> Folly of Tariff-driven Reshoring

Folly of Tariff-driven Reshoring

Source: Science and Technology Daily | 2025-08-12 15:04:10 | Author: Staff Reporters

In April 2025, the Trump administration announced its "reciprocal tariff" policy amid much fanfare, attempting to use the opportunity of trade negotiations to force other countries to pay "protection fees," and  promote reshoring of manufacturing to the U.S.

However, although some industries appeared to experience a brief boom under tariff protection in the short term, it was nothing more than an artificially inflated resurgence. Many global media outlets directly pointed out the real problems: soaring costs, disrupted raw material supplies, broken industrial supply chains, and high prices coupled with low quality becoming the norm. This has led to significant losses for enterprises and increased financial burdens on consumers.

Tariff-driven reshoring limits

"The past three administrations have all attempted and failed to reshore lost manufacturing jobs and we expect the latest effort, with Trump expanding use of tariffs in his second term, to be no different," wrote Capital Economics analyst Thomas Ryan.

Ryan explained that tariffs might support limited production reshoring in certain sectors, such as motor vehicles and pharmaceuticals, because much of the imports in these industries come from developed economies like Canada or Europe, where labor costs are not significantly lower than in the U.S. However, in industries such as textiles and machinery, U.S. companies face competition from low-wage workers in developing countries. He also noted that the U.S. faces a shortage of skilled labor in many industries.

Similar sentiment was echoed by other media. According to the U.S. Bureau of Labor Statistics, as cited by The New York Times (NYT), approximately 400,000 manufacturing positions remain unfilled. NYT noted that experts warn that this gap is likely to widen if companies are compelled to shift production from overseas back to new factories in the U.S.

Fortune magazine commented that people in the U.S. want more U.S. factory jobs, but only if they don't have to work them. According to a Cato Institute survey in 2024, 80 percent of Americans believe the country would benefit from increasing manufacturing employment, but only a quarter think they would be personally better off working in a factory.

Structural barriers in industries

Beyond labor shortages, reshoring to the U.S. also means higher production costs, and comprehensive pressures including regulations, labor and tax burdens. Asia's mature supply chains, efficient manufacturing capabilities, skilled technical workforce, and cost advantages are difficult for the U.S. to replicate in the short term.

The BBC noted that reshoring basic manufacturing sectors like footwear faces structural challenges in U.S. Brands like Nike and Adidas which failed in their attempts a decade ago to develop new manufacturing technologies in the U.S. Today, about 99 percent of shoes sold in the U.S. are imported, mainly from China, Vietnam and Indonesia.

High-tech industries pose even greater challenges. Donald Trump's newest venture, the T1 phone, stopped publicizing that it would be "made-in-America." On its website, the message has been changed to "Designed With American Values." The reality behind this incident is that the U.S. lacks a complete smartphone manufacturing infrastructure — even if assembly takes place domestically, most components still need to be imported from abroad.

Another example is happening in the medical industry. In early July, Trump proposed imposing a 200 percent tariff on imported medicines. Faced with tariff threats, multinational pharmaceutical companies have not only stood their ground but have also accelerated cooperation with Chinese innovative drug firms. Giants like AstraZeneca and Pfizer have actively partnered with Chinese pharmaceutical companies, signing major deals worth billions of dollars.

The Wall Street Journal interviewed experts and manufacturers, who said that if tariffs significantly cut into profits, generic drug companies might simply pull their products from the market rather than continue operating at a loss.

Editor:YU Haoyuan

抱歉,您使用的瀏覽器版本過低或開啟了瀏覽器兼容模式,這會影響您正常瀏覽本網(wǎng)頁

您可以進行以下操作:

1.將瀏覽器切換回極速模式

2.點擊下面圖標升級或更換您的瀏覽器

3.暫不升級,繼續(xù)瀏覽

繼續(xù)瀏覽
临武县| 古田县| 聂荣县| 溧阳市| 察雅县| 宁国市| 确山县| 鸡泽县| 阿城市| 濮阳市| 锦屏县| 临朐县| 扬州市| 特克斯县| 华阴市| 红安县| 宁城县| 南郑县| 乾安县| 洛浦县| 兰州市| 浮梁县| 石景山区| 宁国市| 乌恰县| 林口县| 本溪市| 衡水市| 焉耆| 东莞市| 阳谷县| 郎溪县| 高淳县| 梧州市| 榆树市| 岗巴县| 漾濞| 大英县| 灌云县| 漳浦县| 龙胜|